Recent News

• 06.11.2025 - Lexaria’s DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
• 06.05.2025 - Lexaria Attending BIO International Convention
• 05.12.2025 - Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
• 04.28.2025 - Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
• 04.25.2025 - Lexaria Announces $2 Million Registered Direct Offering of Common Stock
• 04.23.2025 - Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
• 04.03.2025 - Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Recent Filings

• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.28.2025 - EX-99.1 EX-99.1